Sarepta Therapeutics Unveils Restructuring and Pipeline Update for Sustainable Growth
Originally Published 6 months ago — by Sarepta Therapeutics
Sarepta Therapeutics announced a strategic restructuring to focus on high-impact programs, including a workforce reduction and cost savings of approximately $400 million annually, while updating on ELEVIDYS' label and safety measures. The company aims for long-term growth by prioritizing its siRNA platform and maintaining its Duchenne muscular dystrophy portfolio, with key executive appointments and financial highlights for Q2 2025.